{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:24:18Z","timestamp":1787055858907,"version":"build-2736575974"},"reference-count":123,"publisher":"American Chemical Society (ACS)","issue":"16","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001254-01"],"award-info":[{"award-number":["MOH-001254-01"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001334-00"],"award-info":[{"award-number":["MOH-001334-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001388-00"],"award-info":[{"award-number":["MOH-001388-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001483-00"],"award-info":[{"award-number":["MOH-001483-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001740-01"],"award-info":[{"award-number":["MOH-001740-01"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2022\/093\/T1\/Seed-Sep\/06"],"award-info":[{"award-number":["NUHSRO\/2022\/093\/T1\/Seed-Sep\/06"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023 M742149"],"award-info":[{"award-number":["2023 M742149"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202306386"],"award-info":[{"award-number":["tsqn202306386"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","award":["NRF-000352-00"],"award-info":[{"award-number":["NRF-000352-00"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2021\/097\/Startup\/13"],"award-info":[{"award-number":["NUHSRO\/2021\/097\/Startup\/13"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2023\/008\/NUSMed\/TCE\/LOA"],"award-info":[{"award-number":["NUHSRO\/2023\/008\/NUSMed\/TCE\/LOA"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH017"],"award-info":[{"award-number":["ZR2022QH017"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2025QC2148Z"],"award-info":[{"award-number":["ZR2025QC2148Z"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Centers for Precision Oncology Foundation","award":["NUS-P21"],"award-info":[{"award-number":["NUS-P21"]}]},{"name":"2024 Tsinghua-NUS Joint Research Initiative Fund"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"crossref","award":["82203014"],"award-info":[{"award-number":["82203014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"crossref","award":["82572272"],"award-info":[{"award-number":["82572272"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,18]]},"abstract":"<jats:title>Conspectus<\/jats:title>\n                  <jats:p>The advancement of precision medicine depends critically on well-defined molecular targets. Pathologically activated fibroblasts drive disease progression in cancer, fibrosis and chronic inflammation through sustained inflammation, extracellular matrix remodeling and pathological microenvironment formation. Among available markers, fibroblast activation protein (FAP) stands out due to its selective overexpression in diseased tissues versus minimal expression in healthy organs. This unique profile makes FAP a promising target for molecular imaging and targeted therapy, enabling precision theranostics across both oncological and nononcological diseases.<\/jats:p>\n                  <jats:p>FAP-targeted theranostics originated from the lead compound PT-100, which established the core pharmacophore. Subsequent key advance was the replacement of the boronic acid warhead with a cyano group, along with the introduction of fluorine and quinoline moieties, yielding the UAMC-1110 scaffold. This scaffold exhibits improved bioactivity and favorable pharmacokinetics. Systematic modification of the quinoline side chain and conjugation with chelators have allowed efficient radiolabeling, positioning radiolabeled FAP inhibitors as promising tools for precision theranostics. However, continued optimization of UAMC-1110-derived probes to enhance their stability, affinity, tumor retention, and cellular uptake, together with integration into advanced strategies such as nanomedicine, remains essential not only for refining FAP-targeted precision medicine but also for expanding its applications beyond oncology to nononcological diseases.<\/jats:p>\n                  <jats:p>Unlike previous reviews, this Account organizes the field around a unified chemical design language, following a \u201crational design-pharmacokinetics-translational validation\u201d paradigm. After delineating the core biological functions of FAP-expressing fibroblasts in disease pathogenesis, we systematically examine the rapid advancement of radionuclide-labeled FAPIs, including optimization of linkers, chelators, and albumin-binding moieties, along with multimerization strategies, which significantly enhanced the pharmacokinetic profiles. Key innovations in the field include three strategic approaches. First, the albumin-binding therapeutic agent [177Lu]Lu-EB-FAPI achieves prolonged tumor retention and promising efficacy. Second, multimerization strategies have yielded bivalent and tetrameric FAPI constructs, which exhibit superior tumor accumulation. Third, heterodimeric probes such as [68Ga]Ga-FAPI-RGD and [68Ga]Ga-FAPI-LM3 enable dual targeting of FAP along with integrin \u03b1v\u03b23 or somatostatin receptor SSTR2, thereby addressing tumor heterogeneity and enhancing lesion detectability. Subsequently, the application scope of FAPI-based imaging has been expanded from oncology to nononcological diseases. The value of this technique in visualizing dynamic remodeling processes across key pathologic conditions has been established, offering quantitative assessment beyond the reach of standard modalities. Furthermore, we review recent advances in diverse FAP-targeted therapeutic strategies, including nanomaterials, CAR-T cells, and vaccines, and offer a forward-looking perspective on both the potential and the ongoing challenges of FAP as a cross-disease precision theranostic platform.<\/jats:p>","DOI":"10.1021\/acs.accounts.6c00139","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:02:07Z","timestamp":1785891727000},"page":"2615-2634","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Fibroblast\nActivation Protein for Precision\nMedicine"],"prefix":"10.1021","volume":"59","author":[{"given":"Jie","family":"Liu","sequence":"first","affiliation":[{"name":"Shandong First Medical University and Shandong Academy of Medical Sciences , , ,","place":["Jinan, China, 250117"]},{"name":"Shandong Cancer Hospital and Institute , , ,","place":["Jinan, China, 250117"]},{"name":"National University of Singapore , , ,","place":["Singapore, Singapore, 119074"]},{"name":"National University of Singapore , , ,","place":["Singapore, Singapore, 138667"]},{"name":"National University of Singapore , , ,","place":["Singapore, Singapore, 117599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shandong First Medical University and Shandong Academy of Medical Sciences , , ,","place":["Jinan, China, 250117"]},{"name":"Shandong Cancer Hospital and Institute , , ,","place":["Jinan, China, 250117"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifei","family":"Liu","sequence":"additional","affiliation":[{"name":"Shandong First Medical University and Shandong Academy of Medical Sciences , , ,","place":["Jinan, China, 250117"]},{"name":"Shandong Cancer Hospital and Institute , , ,","place":["Jinan, China, 250117"]},{"name":"National University of Singapore , , ,","place":["Singapore, Singapore, 119074"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[{"name":"Shandong First Medical University and Shandong Academy of Medical Sciences , , ,","place":["Jinan, China, 250117"]},{"name":"Shandong Cancer Hospital and Institute , , ,","place":["Jinan, China, 250117"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0870","authenticated-orcid":true,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital and Institute , , ,","place":["Jinan, China, 250117"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-1813","authenticated-orcid":true,"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[{"name":"National University of Singapore , , ,","place":["Singapore, Singapore, 119074"]},{"name":"National University of Singapore , , ,","place":["Singapore, Singapore, 138667"]},{"name":"National University of Singapore , , ,","place":["Singapore, Singapore, 117599"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026081807162749400_cit1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2967\/jnumed.124.268258","article-title":"Comparison\nof [68Ga]Ga-Fibroblast Activation Protein Inhibitor-04\nand [18F]FDG PET Imaging for Solitary Fibrous Tumor and\nPreliminary Application of FAP-Targeted Radiopharmaceutical Therapy","volume":"66","author":"Wang","year":"2025","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.123.266329","article-title":"Fibroblast\nActivation\nProtein-Targeted PET\/CT with 18F-Fibroblast Activation\nProtein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison\nwith 18F-FDG PET\/CT","volume":"65","author":"Xu","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004\nRadioligand Therapy in Patients with End-stage Metastatic\nCancers: A Single-Center, Single-Arm, Phase II Study","volume":"31","author":"Fu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026081807162749400_cit4","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.7150\/thno.86007","article-title":"Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients\nwith lung neoplasms: a pilot exploratory study","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics"},{"key":"2026081807162749400_cit5","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1016\/j.cell.2021.06.024","article-title":"Fibroblasts: Origins,\ndefinitions,\nand functions in health and disease","volume":"184","author":"Plikus","year":"2021","journal-title":"Cell"},{"key":"2026081807162749400_cit6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170499","article-title":"Pulmonary inflammation\nand fibroblast immunoregulation: from bench to bedside","volume":"133","author":"Ghonim","year":"2023","journal-title":"J. Clin. Invest."},{"key":"2026081807162749400_cit7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/path.4115","article-title":"Fibroblast\nautophagy in fibrotic disorders","volume":"229","author":"Principe","year":"2013","journal-title":"J. Pathol."},{"key":"2026081807162749400_cit8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","article-title":"Activated fibroblasts\nin cancer: Perspectives and challenges","volume":"41","author":"Caligiuri","year":"2023","journal-title":"Cancer\nCell"},{"key":"2026081807162749400_cit9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41577-021-00540-z","article-title":"Fibroblasts as immune\nregulators in infection, inflammation and cancer","volume":"21","author":"Davidson","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"2026081807162749400_cit10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation\nprotein in health\nand malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"2026081807162749400_cit11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in Cancer","volume":"6","author":"Kalluri","year":"2006","journal-title":"Nat. Rev.\nCancer"},{"key":"2026081807162749400_cit12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity\nand immunosuppressive environment\nin human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"2026081807162749400_cit13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41467-018-03348-z","article-title":"miR200-regulated CXCL12\u03b2\npromotes fibroblast\nheterogeneity and immunosuppression in ovarian cancers","volume":"9","author":"Givel","year":"2018","journal-title":"Nat. Commun."},{"key":"2026081807162749400_cit14","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP Promotes\nImmunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment\nvia STAT3-CCL2 Signaling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res."},{"key":"2026081807162749400_cit15","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1002\/mc.23782","article-title":"FAP positive\ncancer-associated fibroblasts promote tumor progression and radioresistance\nin esophageal squamous cell carcinoma by transferring exosomal lncRNA\nAFAP1-AS1","volume":"63","author":"Zhou","year":"2024","journal-title":"Mol. Carcinog."},{"key":"2026081807162749400_cit16","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/2326-6066.CIR-18-0098","article-title":"FAP Delineates Heterogeneous and Functionally Divergent\nStromal Cells in Immune-Excluded Breast Tumors","volume":"6","author":"Cremasco","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"2026081807162749400_cit17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12885-019-5353-6","article-title":"Cancer-associated fibroblasts\ninduce\nepithelial-mesenchymal transition of bladder cancer cells through\nparacrine IL-6 signalling","volume":"19","author":"Goulet","year":"2019","journal-title":"BMC Cancer"},{"key":"2026081807162749400_cit18","doi-asserted-by":"publisher","first-page":"217475","DOI":"10.1016\/j.canlet.2025.217475","article-title":"FAP upregulates PD-L1\nexpression in cancer-associated fibroblasts\nto exacerbate T cells dysfunction and suppress anti-tumor immunity","volume":"612","author":"Wei","year":"2025","journal-title":"Cancer Lett."},{"key":"2026081807162749400_cit19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13046-019-1110-6","article-title":"Collagens and Cancer associated fibroblasts\nin the reactive stroma and its relation to Cancer biology","volume":"38","author":"Nissen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2026081807162749400_cit20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41584-025-01259-0","article-title":"Fibroblasts\nin immune\nresponses, inflammatory diseases and therapeutic implications","volume":"21","author":"Zou","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"2026081807162749400_cit21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/imr.12971","article-title":"The inflammatory\nspeech\nof fibroblasts","volume":"302","author":"Schuster","year":"2021","journal-title":"Immunol. Rev."},{"key":"2026081807162749400_cit22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.immuni.2017.01.004","article-title":"Autocrine\nLoop Involving IL-6 Family\nMember LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production\nof Inflammatory Mediators","volume":"46","author":"Nguyen","year":"2017","journal-title":"Immunity"},{"key":"2026081807162749400_cit23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.immuni.2008.07.018","article-title":"Interleukin-17\npromotes autoimmunity by triggering a positive-feedback loop via interleukin-6\ninduction","volume":"29","author":"Ogura","year":"2008","journal-title":"Immunity"},{"key":"2026081807162749400_cit24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3389\/fimmu.2016.00477","article-title":"Stromal Fibroblasts\nin Tertiary Lymphoid\nStructures: A Novel Target in Chronic Inflammation","volume":"7","author":"Barone","year":"2016","journal-title":"Front. Immunol."},{"key":"2026081807162749400_cit25","doi-asserted-by":"publisher","first-page":"217491","DOI":"10.1016\/j.canlet.2025.217491","article-title":"Tertiary lymphoid\nstructures as a biomarker in immunotherapy and\nbeyond: Advancing towards clinical application","volume":"613","author":"Cui","year":"2025","journal-title":"Cancer Lett."},{"key":"2026081807162749400_cit26","doi-asserted-by":"publisher","first-page":"109422","DOI":"10.1016\/j.celrep.2021.109422","article-title":"Immune\nmechanisms orchestrate tertiary lymphoid structures in tumors via\ncancer-associated fibroblasts","volume":"36","author":"Rodriguez","year":"2021","journal-title":"Cell Rep."},{"key":"2026081807162749400_cit27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1096\/fj.11-186098","article-title":"Cadherin-11 contributes to pulmonary fibrosis: potential\nrole in TGF-\u03b2 production and epithelial to mesenchymal transition","volume":"26","author":"Schneider","year":"2012","journal-title":"FASEB J."},{"key":"2026081807162749400_cit28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24676","article-title":"IL-11 is a crucial\ndeterminant of cardiovascular fibrosis","volume":"552","author":"Schafer","year":"2017","journal-title":"Nature"},{"key":"2026081807162749400_cit29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2401899121","article-title":"Leukemia\ninhibitory factor (LIF) receptor amplifies pathogenic activation of\nfibroblasts in lung fibrosis","volume":"121","author":"Nguyen","year":"2024","journal-title":"Proc. Natl. Acad.\nSci. U. S. A."},{"key":"2026081807162749400_cit30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1067-1927.2005.130102.x","article-title":"Tissue repair, contraction, and the\nmyofibroblast","volume":"13","author":"Desmoulie\u0300re","year":"2005","journal-title":"Wound. Repair. Regen."},{"key":"2026081807162749400_cit31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct\nmechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"2026081807162749400_cit32","doi-asserted-by":"publisher","first-page":"C216","DOI":"10.1152\/ajpcell.00328.2012","article-title":"Cellular mechanisms\nof tissue fibrosis. 1. Common and\norgan-specific mechanisms associated with tissue fibrosis","volume":"304","author":"Zeisberg","year":"2013","journal-title":"Am. J. Physiol Cell Physiol"},{"key":"2026081807162749400_cit33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid\nArthritis - Common Origins, Divergent Mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"2026081807162749400_cit34","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/ard.61.11.975","article-title":"Invasive properties\nof fibroblast-like synoviocytes: correlation with growth characteristics\nand expression of MMP-1, MMP-3, and MMP-10","volume":"61","author":"Tolboom","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"2026081807162749400_cit35","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/art.23653","article-title":"Cytokine-controlled\nRANKL and osteoprotegerin expression by human and mouse synovial fibroblasts:\nfibroblast-mediated pathologic bone resorption","volume":"58","author":"Tunyogi-Csapo","year":"2008","journal-title":"Arthritis Rheum."},{"key":"2026081807162749400_cit36","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.3390\/cancers14184394","article-title":"Cancer-Associated\nFibroblasts: The Origin, Biological Characteristics and Role in Cancer-A\nGlance on Colorectal Cancer","volume":"14","author":"Fotsitzoudis","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026081807162749400_cit37","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1742-4658.2011.08051.x","article-title":"Neuropeptide Y,\nB-type natriuretic peptide, substance P and peptide YY are novel substrates\nof fibroblast activation protein-\u03b1","volume":"278","author":"Keane","year":"2011","journal-title":"FEBS\nJ."},{"key":"2026081807162749400_cit38","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1158\/0008-5472.CAN-04-0447","article-title":"PT-100, a small molecule dipeptidyl peptidase inhibitor,\nhas potent antitumor effects and augments antibody-mediated cytotoxicity\nvia a novel immune mechanism","volume":"64","author":"Adams","year":"2004","journal-title":"Cancer Res."},{"key":"2026081807162749400_cit39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective Inhibitors of Fibroblast\nActivation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine\nScaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"2026081807162749400_cit40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","article-title":"Targeting\nfibroblast activation protein (FAP): next generation PET radiotracers\nusing squaramide coupled bifunctional DOTA and DATA5m chelators","volume":"5","author":"Moon","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"2026081807162749400_cit41","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor\nRadiopharmaceuticals for Cancer Therapy","volume":"63","author":"Xu","year":"2022","journal-title":"J.\nNucl. Med."},{"key":"2026081807162749400_cit42","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.3390\/molecules29133093","article-title":"Tailoring Fibroblast-Activation\nProtein Targeting for Theranostics: A Comparative Preclinical Evaluation\nof the 68Ga- and 177Lu-Labeled Monomeric and\nDimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and\nDOTAGA.(SA.FAPi)2","volume":"29","author":"La\u0308ppchen","year":"2024","journal-title":"Molecules"},{"key":"2026081807162749400_cit43","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A Tumor-Imaging\nMethod Targeting Cancer-Associated Fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit44","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development\nof Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast\nActivation Protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: Biodistribution\nand Preliminary Dosimetry Estimate\nof 2 DOTA-Containing FAP-Targeting Agents in Patients with Various\nCancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit46","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00259-021-05646-z","article-title":"[18F]FAPI-42 PET imaging in cancer patients:\noptimal acquisition time,\nbiodistribution, and comparison with [68Ga]Ga-FAPI-04","volume":"49","author":"Hu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit47","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development\nof Fibroblast Activation Protein-Targeted Radiotracers with Improved\nTumor Retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit48","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s00259-025-07108-2","article-title":"FAP-targeted\nPET\/CT imaging in patients\nwith breast cancer from a prospective bi-center study: insights into\ndiagnosis and clinic management","volume":"52","author":"Guo","year":"2025","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"key":"2026081807162749400_cit49","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1007\/s00259-025-07361-5","article-title":"Evaluation\nof locoregional invasiveness of early lung adenocarcinoma manifesting\nas ground-glass nodules via [68Ga]Ga-FAPI-46 PET\/CT imaging","volume":"52","author":"Ruan","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit50","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00259-021-05634-3","article-title":"FAP-targeted\nradionuclide therapy\nwith [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma","volume":"49","author":"Fu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit51","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and\nEfficacy of 90Y-FAPI-46 Radioligand Therapy in Patients\nwith Advanced Sarcoma and Other Cancer Entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"2026081807162749400_cit52","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2967\/jnumed.123.266411","article-title":"Fibroblast Activation Protein \u03b1-Directed\nImaging and Therapy of Solitary Fibrous Tumor","volume":"65","author":"Hamacher","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit53","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00259-020-05132-y","article-title":"Biodistribution, pharmacokinetics,\ndosimetry of [68Ga]Ga-DOTA.SA.FAPi,\nand the head-to-head comparison with [18F]F-FDG PET\/CT\nin patients with various cancers","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"key":"2026081807162749400_cit54","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.3390\/molecules26123482","article-title":"In Vitro Evaluation of the Squaramide-Conjugated Fibroblast\nActivation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi\nand DOTA.SA.FAPi","volume":"26","author":"Moon","year":"2021","journal-title":"Molecules"},{"key":"2026081807162749400_cit55","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3390\/ph14121212","article-title":"First-In-Human Results\non the Biodistribution,\nPharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi\nand [177Lu]Lu-DOTAGA.(SA.FAPi)2","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026081807162749400_cit56","doi-asserted-by":"publisher","first-page":"e444","DOI":"10.1097\/RLU.0000000000004164","article-title":"First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case\nof Aggressive Medullary Thyroid\nCarcinoma Clinically Mimicking as Anaplastic Thyroid Cancer","volume":"47","author":"Ballal","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"2026081807162749400_cit57","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00259-022-05758-0","article-title":"[18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution,\nand PET\/CT imaging of various cancers","volume":"49","author":"Wei","year":"2022","journal-title":"Eur.\nJ. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit58","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222785","article-title":"FAPI Compared\nwith\nFDG PET\/CT for Diagnosis of Primary and Metastatic Lung Cancer","volume":"308","author":"Wei","year":"2023","journal-title":"Radiology"},{"key":"2026081807162749400_cit59","doi-asserted-by":"publisher","first-page":"12940","DOI":"10.1021\/acs.jmedchem.5c00837","article-title":"Design, Structure Optimization, and Preclinical Evaluation\nof 188Re-Labeled FAPI for Targeted Radionuclide Therapy","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026081807162749400_cit60","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1021\/acs.molpharmaceut.3c00886","article-title":"Synthesis and Preliminary Study of 99mTc-Labeled\nHYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors","volume":"21","author":"Ma","year":"2024","journal-title":"Mol. Pharmaceutics"},{"key":"2026081807162749400_cit61","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified\nradiolabeled fibroblast activation protein inhibitor\nas long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics"},{"key":"2026081807162749400_cit62","doi-asserted-by":"publisher","first-page":"8245","DOI":"10.1021\/acs.jmedchem.1c02162","article-title":"Rational Design\nand\nPharmacomodulation of Protein-Binding Theranostic Radioligands for\nTargeting the Fibroblast Activation Protein","volume":"65","author":"Meng","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026081807162749400_cit63","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00259-021-05591-x","article-title":"Fatty acid-conjugated\nradiopharmaceuticals for fibroblast activation\nprotein-targeted radiotherapy","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"key":"2026081807162749400_cit64","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast\nActivation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer:\nFirst-in-Human, Dose-Escalation Study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin.\nCancer Res."},{"key":"2026081807162749400_cit65","doi-asserted-by":"publisher","first-page":"4s","DOI":"10.2967\/jnumed.123.266983","article-title":"Fibroblast Activation\nProtein Inhibitor Tracers and Their Preclinical, Translational, and\nClinical Status in China","volume":"65","author":"Zhao","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit66","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor\nefficacy and potential mechanism of FAP-targeted radioligand\ntherapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct .Target Ther."},{"key":"2026081807162749400_cit67","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","article-title":"Development\nof FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand\nTherapy","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit68","first-page":"476","article-title":"Fibroblast Activation\nProtein (FAP)\ntargeting homodimeric FAP inhibitor radiotheranostics: a step to improve\ntumor uptake and retention time","volume":"11","author":"Moon","year":"2021","journal-title":"Am. J. Nucl.\nMed. Mol. Imaging"},{"key":"2026081807162749400_cit69","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/cancers15061889","article-title":"Novel Generation of FAP Inhibitor-Based\nHomodimers for Improved Application in Radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026081807162749400_cit70","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00259-025-07565-9","article-title":"Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human\ndosimetry extrapolation to lutetium-177 and terbium-161 analogs","volume":"53","author":"Bilinska","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit71","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00259-023-06482-z","article-title":"Therapeutic\npotential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic\nbreast cancer patients with limited treatment options: efficacy and\nsafety assessment","volume":"51","author":"Yadav","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit72","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00259-024-06703-z","article-title":"Clinical translation\nof a novel FAPI dimer [68Ga]Ga-LNC1013","volume":"51","author":"Tan","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit73","doi-asserted-by":"publisher","first-page":"47869","DOI":"10.1021\/acsami.5c07340","article-title":"Theranostic Potential\nof [68Ga]Ga\/[177Lu]Lu-LNC1013: A Dual-Purpose\nLigand for Cancer Imaging and Radionuclide Therapy","volume":"17","author":"Wang","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2026081807162749400_cit74","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.7150\/thno.79144","article-title":"Synthesis, preclinical\nevaluation and radiation dosimetry of a dual\ntargeting PET tracer [68Ga]Ga-FAPI-RGD","volume":"12","author":"Zang","year":"2022","journal-title":"Theranostics"},{"key":"2026081807162749400_cit75","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.7150\/thno.113070","article-title":"Comparative study of [18F]AlF-NOTA-FAPI-RGD and [18F]FDG\/[18F]AlF-NOTA-FAPI-04 PET\/CT in renal cell\ncarcinoma","volume":"15","author":"Gao","year":"2025","journal-title":"Theranostics"},{"key":"2026081807162749400_cit76","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2967\/jnumed.123.266183","article-title":"Design, Preclinical\nEvaluation, and Clinical Translation of 68Ga-FAPI-LM3,\na Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma","volume":"65","author":"Zhao","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit77","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility,\nBiodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide\nTherapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286:\nFirst-in-Humans Results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit78","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/RLU.0000000000005258","article-title":"177 Lu-FAP-2286 Therapy\nin a Patient With Metastatic Rhabdoid Meningioma","volume":"49","author":"Wan","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"2026081807162749400_cit79","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.122.264544","article-title":"PET Imaging\nof Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit80","doi-asserted-by":"publisher","first-page":"108541","DOI":"10.1016\/j.isci.2023.108541","article-title":"3BP-3940,\na highly potent FAP-targeting peptide for theranostics - production,\nvalidation and first in human experience with Ga-68 and Lu-177","volume":"26","author":"Greifenstein","year":"2023","journal-title":"iScience"},{"key":"2026081807162749400_cit81","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2967\/jnumed.123.266345","article-title":"Preclinical development of PNT6555, a boronic acid-based, fibroblast\nactivation protein-\u03b1 (FAP)-targeted radiotheranostic for imaging\nand treatment of FAP-positive tumors","volume":"65","author":"Poplawski","year":"2024","journal-title":"J. Nucl.\nMed."},{"key":"2026081807162749400_cit82","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/ph16060798","article-title":"Synthesis and Preclinical Evaluation\nof Novel 68Ga-Labeled (R)-Pyrrolidin-2-yl-boronic Acid-Based\nPET Tracers for Fibroblast Activation Protein-Targeted Cancer Imaging","volume":"16","author":"Bendre","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026081807162749400_cit83","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2967\/jnumed.122.264036","article-title":"A Dimeric\nFAP-Targeting Small-Molecule Radioconjugate with High and Prolonged\nTumor Uptake","volume":"63","author":"Galbiati","year":"2022","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit84","doi-asserted-by":"publisher","first-page":"13392","DOI":"10.1021\/acs.jmedchem.4c01295","article-title":"Molecular\nEvolution of Multivalent\nOncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor\nRetention","volume":"67","author":"Galbiati","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026081807162749400_cit85","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.2967\/jnumed.124.268200","article-title":"Preclinical\nEvaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted\nRadiopharmaceutical Therapeutic\nfor Solid Tumors","volume":"65","author":"Galbiati","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit86","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s41181-024-00283-x","article-title":"In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide\ntheranostics and other oncological interventions","volume":"9","author":"van der Heide","year":"2024","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026081807162749400_cit87","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00259-024-06878-5","article-title":"Enhanced detection\nof damaged myocardium and risk stratification in hypertrophic cardiomyopathy\nusing integrated [68Ga]Ga-FAPI-04 PET\/CMR imaging","volume":"52","author":"Ding","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit88","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2967\/jnumed.119.226993","article-title":"Molecular Imaging of Fibroblast Activity\nAfter Myocardial Infarction Using a 68Ga-Labeled Fibroblast\nActivation Protein Inhibitor, FAPI-04","volume":"60","author":"Varasteh","year":"2019","journal-title":"J. Nucl.\nMed."},{"key":"2026081807162749400_cit89","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jcmg.2024.10.001","article-title":"Molecular Stratification of Light-Chain Cardiac Amyloidosis With 18F-Florbetapir and 68Ga-FAPI-04 for Enhanced Prognostic\nPrecision","volume":"18","author":"Wang","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026081807162749400_cit90","doi-asserted-by":"publisher","first-page":"948","DOI":"10.2967\/jnumed.121.262863","article-title":"Feasibility of in vivo imaging of fibroblast activation\nprotein in\nhuman arterial walls","volume":"63","author":"Wu","year":"2022","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit91","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-022-05962-y","article-title":"Early detection\nof radiation-induced myocardial damage by [18F]AlF-NOTA-FAPI-04\nPET\/CT imaging","volume":"50","author":"Wei","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit92","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/RLU.0000000000003692","article-title":"68Ga-FAPI PET\/CT Versus 18F-FDG PET\/CT for the Evaluation\nof Disease Activity in Takayasu Arteritis","volume":"46","author":"Wu","year":"2021","journal-title":"Clin.\nNucl. Med."},{"key":"2026081807162749400_cit93","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.121.263555","article-title":"Cardiac fibroblast activation in\npatients early after acute myocardial infarction: integration with\nMR tissue characterization and subsequent functional outcome","volume":"63","author":"Diekmann","year":"2022","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit94","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1007\/s00259-024-06773-z","article-title":"Non-invasive visualization\nof liver fibrosis with [68Ga] Ga-DOTA-FAPI-04 PET from\npreclinical insights to clinical translation","volume":"51","author":"Song","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit95","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1007\/s00259-022-05814-9","article-title":"[68 Ga]\nGa-FAPI-46 PET for non-invasive\ndetection of pulmonary fibrosis disease activity","volume":"49","author":"Rosenkrans","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit96","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00259-023-06564-y","article-title":"Initial results\nwith [18F] FAPI-74 PET\/CT in idiopathic pulmonary fibrosis","volume":"51","author":"Mori","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit97","doi-asserted-by":"publisher","first-page":"102598","DOI":"10.1016\/j.eclinm.2024.102598","article-title":"FAPi PET\/CT for assessment\nand visualisation\nof active myositis-related interstitial lung disease: a prospective\nobservational pilot study","volume":"72","author":"Kastrati","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026081807162749400_cit98","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2967\/jnumed.124.268351","article-title":"Correlation of FAPI\nPET Uptake with Immunohistochemistry\nin Explanted Lungs from Patients with Advanced Interstitial Lung Disease","volume":"65","author":"Hotta","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026081807162749400_cit99","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1021\/acs.molpharmaceut.4c00405","article-title":"Enhanced Detection\nof Early Pulmonary Fibrosis Disease Using 68Ga-FAPI-LM3\nPET","volume":"21","author":"Chen","year":"2024","journal-title":"Mol. Pharmaceutics"},{"key":"2026081807162749400_cit100","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1007\/s00259-022-05836-3","article-title":"Preclinical\nevaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04\nfor PET imaging of rheumatoid arthritis","volume":"49","author":"Ge","year":"2022","journal-title":"Eur.\nJ. Nucl. Med. Mol. Imaging"},{"key":"2026081807162749400_cit101","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.7150\/thno.102627","article-title":"Dual targeting heterodimer\nPET tracer [18F]AlF-FAPI-RGD in patients with rheumatoid\narthritis: a pilot exploratory study","volume":"14","author":"Wang","year":"2024","journal-title":"Theranostics"},{"key":"2026081807162749400_cit102","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1007\/s00259-025-07310-2","article-title":"Fibroblast activation protein-targeted\nPET\/CT with 68Ga-FAPI-46\nfor evaluation of structural damage and inflammation in axial spondyloarthritis:\na prospective study","volume":"52","author":"Chen","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol.\nImaging"},{"key":"2026081807162749400_cit103","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1021\/acs.molpharmaceut.5c01192","article-title":"Construction of 89Zr-Radiolabeled Melanin-Based\nNanoprobes with FAP-Targeted Motifs for Tumor PET Imaging","volume":"22","author":"Wei","year":"2025","journal-title":"Mol. Pharmaceutics"},{"key":"2026081807162749400_cit104","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1021\/acsnano.8b09607","article-title":"An Extendable\nStar-Like Nanoplatform for Functional and Anatomical\nImaging-Guided Photothermal Oncotherapy","volume":"13","author":"Han","year":"2019","journal-title":"ACS\nNano"},{"key":"2026081807162749400_cit105","doi-asserted-by":"publisher","first-page":"2309279","DOI":"10.1002\/smll.202309279","article-title":"Biomimetic Nanoplatform for Dual-Targeted\nClearance of Activated and Senescent Cancer-Associated Fibroblasts\nto Improve Radiation Resistance in Breast Cancer","volume":"20","author":"Jian","year":"2024","journal-title":"Small"},{"key":"2026081807162749400_cit106","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.2147\/IJN.S497428","article-title":"Injured Cardiac Tissue-Targeted\nDelivery\nof TGF\u03b21 siRNA by FAP Aptamer-Functionalized Extracellular Vesicles\nPromotes Cardiac Repair","volume":"20","author":"Kang","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"2026081807162749400_cit107","doi-asserted-by":"publisher","first-page":"113888","DOI":"10.1016\/j.jconrel.2025.113888","article-title":"In vivo FAP-CAR macrophages enhance chemotherapy\nand immunotherapy against pancreatic cancer by removing the fibrosis\nbarrier","volume":"384","author":"Wang","year":"2025","journal-title":"J. Controlled Release"},{"key":"2026081807162749400_cit108","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1186\/s12951-024-02946-y","article-title":"Targeting FAP-positive\nchondrocytes in osteoarthritis: a novel lipid\nnanoparticle siRNA approach to mitigate cartilage degeneration","volume":"22","author":"Zhao","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"2026081807162749400_cit109","doi-asserted-by":"publisher","first-page":"10337","DOI":"10.1021\/acsnano.3c00764","article-title":"Nanovaccine Displaying\nImmunodominant T Cell Epitopes of Fibroblast Activation Protein Is\nEffective Against Desmoplastic Tumors","volume":"17","author":"Shin","year":"2023","journal-title":"ACS Nano"},{"key":"2026081807162749400_cit110","doi-asserted-by":"publisher","first-page":"14028","DOI":"10.1021\/acs.jmedchem.1c01010","article-title":"Regulation\nof Fibroblast Activation Protein-\u03b1 Expression: Focus on Intracellular\nProtein Interactions","volume":"64","author":"Juillerat-Jeanneret","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026081807162749400_cit111","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.7150\/thno.41409","article-title":"Design and validation\nof fibroblast activation protein\nalpha targeted imaging and therapeutic agents","volume":"10","author":"Roy","year":"2020","journal-title":"Theranostics"},{"key":"2026081807162749400_cit112","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-07-5211","article-title":"Effective immunoconjugate\ntherapy\nin cancer models targeting a serine protease of tumor fibroblasts","volume":"14","author":"Ostermann","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2026081807162749400_cit113","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/1535-7163.MCT-15-0647","article-title":"RG7386, a\nNovel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent,\nAvidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis","volume":"15","author":"Bru\u0308nker","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"2026081807162749400_cit114","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-20-4001","article-title":"Fibroblast\nActivation Protein \u03b1-Targeted CD40 Agonism Abrogates Systemic\nToxicity and Enables Administration of High Doses to Induce Effective\nAntitumor Immunity","volume":"27","author":"Sum","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2026081807162749400_cit115","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T cells secreting\nanti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma\nand its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"2026081807162749400_cit116","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/CIRCRESAHA.124.325212","article-title":"CAR-Macrophage Therapy Alleviates\nMyocardial Ischemia-Reperfusion Injury","volume":"135","author":"Wang","year":"2024","journal-title":"Circ.\nRes."},{"key":"2026081807162749400_cit117","doi-asserted-by":"publisher","first-page":"114760","DOI":"10.1016\/j.intimp.2025.114760","article-title":"Fibroblast activation\nprotein-targeted chimeric antigen-receptor-modified NK cells alleviate\ncardiac fibrosis","volume":"157","author":"Zheng","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"2026081807162749400_cit118","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-17-2033","article-title":"Alteration\nof the tumor stroma using a consensus DNA vaccine targeting fibroblast\nactivation protein (FAP) synergizes with antitumor vaccine therapy\nin mice","volume":"24","author":"Duperret","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2026081807162749400_cit119","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/CIRCRESAHA.124.325017","article-title":"A vaccine against fibroblast\nactivation\nprotein improves murine cardiac fibrosis by preventing the accumulation\nof myofibroblasts","volume":"136","author":"Yoshida","year":"2025","journal-title":"Circ. Res."},{"key":"2026081807162749400_cit120","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2967\/jnumed.122.264494","article-title":"Fibroblast Activation\nProtein-Targeted Radioligand\nTherapy for Treatment of Solid Tumors","volume":"64","author":"Lindeman","year":"2023","journal-title":"J. Med.\nChem."},{"key":"2026081807162749400_cit121","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical\nevaluation of FAP-2286 for fibroblast activation protein targeted\nradionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"key":"2026081807162749400_cit122","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40658-022-00497-5","article-title":"Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts\nmodel","volume":"9","author":"Tranel","year":"2022","journal-title":"EJNMMI Phys."},{"key":"2026081807162749400_cit123","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated\nfibroblasts and fibrosis induces immunosuppression and accelerates\npancreas cancer with reduced survival","volume":"25","author":"O\u0308zdemir","year":"2014","journal-title":"Cancer\nCell"}],"container-title":["Accounts of Chemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.accounts.6c00139","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/achre4\/article-pdf\/59\/16\/2615\/66394690\/acs.accounts.6c00139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/achre4\/article-pdf\/59\/16\/2615\/66394690\/acs.accounts.6c00139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:24:44Z","timestamp":1787052284000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/achre4\/article\/59\/16\/2615\/5243712\/Targeting-Fibroblast-Activation-Protein-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":123,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8,4]]},"published-print":{"date-parts":[[2026,8,18]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.accounts.6c00139","relation":{},"ISSN":["0001-4842","1520-4898"],"issn-type":[{"value":"0001-4842","type":"print"},{"value":"1520-4898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}